首页> 美国卫生研究院文献>Frontline Gastroenterology >Research: Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent
【2h】

Research: Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent

机译:研究:脂肪性肝病中肝纤维化的非侵入性标志物在南亚裔人群中不可靠

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

ObjectiveLiver biopsy is the most accurate method for determining stage and grade of injury in non-alcoholic fatty liver disease (NAFLD). Given risks and limitations of biopsy, non-invasive tests such as NAFLD fibrosis score, aspartate transaminase (AST) to platelet ratio index, Fib-4, AST/alanine transaminase ratio and BARD are used. Prevalence and severity of NAFLD and metabolic syndrome vary by ethnicity, yet tests have been developed in largely white populations. We tested our hypothesis that non-invasive tests that include metabolic parameters are less accurate in South Asian compared with white patients.
机译:目的肝活检是确定非酒精性脂肪性肝病(NAFLD)损伤的阶段和等级的最准确方法。考虑到活检的风险和局限性,使用非侵入性检查,例如NAFLD纤维化评分,天冬氨酸转氨酶(AST)与血小板的比率指数,Fib-4,AST /丙氨酸转氨酶比率和BARD。 NAFLD和代谢综合征的患病率和严重程度因种族而异,但已经在大部分白人人群中进行了测试。我们检验了这一假设,即与白人患者相比,包括代谢参数在内的非侵入性检查在南亚地区的准确性较差。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号